Loop Diuretic Therapy in Acutely Decompensated Heart Failure

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

DiurHF is a prospective, multicenter, observational, study that compares continuous with intermittent infusion of furosemide in patients admitted with a diagnosis of ADHF. Previous pilot study design was planned to anticipate a larger multicenter trial able to definitively evaluate the optimal loop diuretic use strategy in patients with ADHF.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Siena
• Collaborators: Azienda Ospedaliera di Padova; Azienda Ospedaliera Sant'Andrea; Ospedale Madonna della Navicella; University of Roma La Sapienza
• Treatments: Diuretics; Furosemide; Sodium Potassium Chloride Symporter Inhibitors

Criteria

Inclusion Criteria:

• Patients over 18 years;

• Patients with diagnosis of ADHF(dyspnea, orthopnea, peripheral edema or major fatigue and at least two clinical signs including rales, hepatomegaly, pulmonary congestion on chest radiography, jugular vein dilatation, or a third heart sound);

• Blood BNP > 100 pg/mL;

ADHF: Acute Decompensated Heart Failure; BNP: B-type Natriuretic Peptide; IV: IntraVenous; LVEF: Left Ventricular Ejection Fraction.

Exclusion Criteria:

• Patients who receive more than 40 mg of IV furosemide;

• End-Stage renal disease or renal replacement therapy;

• Recent myocardial infarction (within thirty days of screening);

• Systolic blood pressure < 80 mmHg;

• Creatinine levels > 4 mg/dL;

• Patients affected by sepsis, liver diseases, inflammatory diseases or neoplastic diseases.